COVID-19 mRNA Vaccine Targeting Omicron JN.1 Lineage Safe
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Aug. 6, 2025 -- Vaccination with the updated COVID-19 mRNA vaccine containing the severe acute respiratory syndrome coronavirus-2 Omicron JN.1 lineage was not associated with an increased risk for 29 adverse events, according to a study published online July 28 in JAMA Network Open.
Niklas Worm Andersson, M.D., Ph.D., from Statens Serum Institut in Copenhagen, Denmark, and colleagues examined the association between vaccination with JN.1-containing vaccines and the risk for 29 serious adverse events adapted from prioritized lists of adverse events of special interest to COVID-19 vaccines. Outcome rates during the first 28 days after JN.1-containing vaccine administration (i.e., the risk period) were compared to outcome rates during the remaining period.
Participants were adults in Denmark recommended to receive the 2024 to 2025 JN.1-containing booster vaccine who had previously received three or more COVID-19 vaccine doses (1,012,400 individuals). The researchers found that during the 28-day risk period after receipt of a JN.1-containing mRNA vaccine, there were no significant increases in the rate of hospital contacts for any of 29 adverse events compared with reference period rates. The incidence rate ratios were 0.84 (95 percent confidence interval [CI], 0.76 to 0.94), 0.92 (95 percent CI, 0.76 to 1.13), and 1.12 (95 percent CI, 0.41 to 3.10) for ischemic cardiac events, intracranial bleeding, and myocarditis, respectively.
"Although we analyzed a nationwide cohort, some outcomes, such as erythema multiforme, occurred very rarely during follow-up, with consequently lower statistical precision, and some outcomes, such as transverse myelitis, could not be statistically compared," the authors write.
One author disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2025
Further Support and Information on COVID-19
Read this next
Larazotide May Speed Recovery in Children With Multisystem Inflammatory Syndrome
WEDNESDAY, Aug. 6, 2025 -- Treatment of multisystem inflammatory syndrome in children (MISC), a postacute sequela of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)...
Prevalence of Disorders of Gut-Brain Interaction Increased After Pandemic
TUESDAY, Aug. 5, 2025 -- The prevalence of disorders of the gut-brain interaction (DGBI) increased from before to after the COVID-19 pandemic, according to a study published...
Study Estimates COVID-19 Vaccinations Prevented More Than 2.5 Million Deaths in 2020 to 2024
MONDAY, Aug. 4, 2025 -- COVID-19 vaccination during 2020 to 2024 was beneficial, but estimates are more conservative than previous calculations that focused on the first year of...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.